Protara Therapeutics has no meaningful revenue across the ten quarters shown, while operating losses roughly doubled from -$11.9M in 2024Q1 to -$23.3M in 2026Q2, driven mainly by R&D expense rising from $7.7M to $17.0M per quarter.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 6, 2026 | -$0.35+4.3% vs -$0.37 | — vs — |
Q3 2026 Aug 11, 2026 | -$0.36-10.5% vs -$0.33 | — vs — |
Q2 2026 May 13, 2026 | -$0.31+13.9% vs -$0.36 | — vs — |
Q2 2026 Mar 10, 2026 | -$0.37-15.6% vs -$0.32 | — vs — |
Expect to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial of TARA-002 in NMIBC by year-end 2026
Company remains on track to report interim results from Phase 2b cohort in 4Q 2026 NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage biotechnology company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it has completed enrollment of the Phase 2b, open-label dose confirmation phase of the THRIVE-3 clinical trial evaluating IV Choline Chloride in patients with intestinal failure who are dependent on parenteral support (PS). The dose confirmation phase of the trial includes 24 patients.
NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026, at 2:00 pm ET.
Bank of America Corp DE grew its stake in shares of Protara Therapeutics, Inc. (NASDAQ: TARA) by 86.7% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 925,918 shares of the company's stock after buying an additional 430,014 shares during
Benchmark TARA against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Protara Therapeutics, Inc. (TARA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.30 | $129.27M | -1.84 | — | — | -46.15% | — | |
| $2.38 | $259.88M | -15.80 | — | — | -5.76% | — | |
| $15.43 | $1.52B | -3.01 | 20.13% | -71.78% | — | — | |
| $21.23 | $3.64B | 10.28 | 11.87% | 30.13% | 28.03% | — | |
| $7.97 | $417.26M | -17.11 | -92.84% | -45.43% | -8.34% | — | |
| $24.75 | $1.21B | -19.03 | 21.45% | -26.27% | — | — |
Protara Therapeutics, Inc. (TARA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Protara Therapeutics, Inc. (TARA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 11, 2026·SEC
Jun 29, 2026·SEC
Jun 15, 2026·SEC
Get notified when TARA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Protara Therapeutics, Inc. (TARA) stock FAQ — growth, dividends, profitability & financials explained
No. Protara Therapeutics, Inc. (TARA) reported a net loss of $78.4M over the trailing twelve months.
Protara Therapeutics, Inc. (TARA) had a return on equity (ROE) of -46.1% over the trailing twelve months. A negative ROE means the company lost money over the period.
Protara Therapeutics, Inc. (TARA) had negative free cash flow of $73.2M over the trailing twelve months.
